Podcast:BioSpace Published On: Thu Oct 10 2024 Description: Designating something "safe" in this industry means acceptable risk. AI can help us improve acceptable risks if it is used appropriately. However, industry experts must be thoughtful and responsible in their use of AI within clinical trials. In the third episode of our mini series on artificial intelligence, our guests explore the challenges and benefits of integrating technology into the lives of patients. Host Lori Ellis, Head of Insights, BioSpace Guests Mike King, Senior Director of Product and Strategy, IQVIA Moritz von Stosch Chief Innovation Officer, DataHow Nindhana Paranthaman, Executive Medical Director, Clinical Development, Summit Therapeutics Paul Agapow, Head of Data Science, BioNTech